Retatrutide vs Tesamorelin
Extensively Studied vs FDA Approved
monitor Mechanism-based · 55% Both Retatrutide and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Retatrutide Tesamorelin
Weight 4,731.33 Da 5,135.9 Da
Half-life ~6 days 26-38 minutes
Chain 39 amino acids 44 amino acids
Type Triple GLP-1/GIP/glucagon agonist GHRH analog
Key Benefits
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
Retatrutide Tesamorelin
Status Extensively Studied FDA Approved
References 6 studies 5 studies
Latest 2025-10 June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.